Verdict comes in a Zantac lawsuit against GlaxoSmithKline and Boehringer Ingelheim, weeks after Sanofi and Pfizer announced agreements to settle thousands of Zantac cancer claims.
Glaxo first discovered a link between NDMA in Zantac and cancer at least four decades ago, according to the lawsuit filed by the independent testing lab that uncovered the cancer risks associated with the heartburn drug
GlaxoSmithKline reportedly faces the bulk of the remaining Zantac cancer lawsuits, with the first case of more than 70,000 claims currently going before a jury in Chicago.
A Zantac recall in 2019 has led to years of litigation against several different drug makers, over cancer-causing chemicals in the widely used heartburn drug.
Jury is hearing evidence after several prior Zantac cancer lawsuits were settled weeks before trial was set to begin in other courts.
Sanofi will pay $100 million to resolve about 4,000 claims over toxic chemicals in the recalled heartburn drug, but tens of thousands of additional Zantac cancer lawsuits remain unsettled, with most pending in Delaware state court.
Deal comes as a Delaware judge is currently weighing whether to accept or reject plaintiffs' expert witness testimony in more than 70,000 other Zantac lawsuits still pending in that state.
Second time in the last month GlaxoSmithKline has reached a Zantac settlement agreement just before a case was set to go before a jury, privately resolving claims that the recalled heartburn drug caused cancer
Although GlaxoSmithKline has agreed to several Zantac settlements payouts in recent months, the drug maker indicates that it plans to continue defending against cancer lawsuits being pursued by former users of Zantac.
GlaxoSmithKline, Boehringer Ingelheim, Pfizer and other drug makers face more than 70,000 Zantac cancer lawsuits in Delaware state court, after a U.S. District Judge dimissed all claims filed in the federal court system in 2022.
